Eli Lilly (LLY) Shatters Records: Post-Earnings Surge Sends Stock to Stratospheric Highs
Pharma giant Eli Lilly just mooned like a meme stock—except this rally's fueled by actual earnings, not Reddit hype.
The breakout: LLY shares punched through all-time highs as institutional investors piled in post-earnings. No speculative frenzy here—just cold, hard clinical trial wins and FDA nods doing the heavy lifting.
Wall Street's dilemma: Chase the momentum or wait for the inevitable 'sell the news' pullback? Meanwhile, retail traders are too busy losing money on crypto to notice a traditional stock actually delivering fundamentals.
Bottom line: When Big Pharma outperforms Big Tech, maybe it's time to rethink what 'growth stock' really means in 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
LLY stock ROSE 4.8% on Nov. 10 to close at a record high of $966.55. The previous record close of $960.02 occurred on Aug. 30, 2024. In afternoon trading on Nov. 11, Eli Lilly’s stock was up another 2.43% and hit an intra-day all-time high of $999.95.
The rise in LLY stock is a sharp reversal from earlier this year when the share price languished over concerns about demand for its weight-loss drugs and price controls on pharmaceuticals that could be imposed by U.S. President Donald Trump. Even with the current rally, Eli Lilly’s stock is only up 18% over the past 12 months.
Catalysts
Eli Lilly’s stock has been rallying due to two catalysts that have emerged over the past month. The first was the company’s third-quarter print. Eli Lilly reported earnings per share (EPS) of $7.02, which was far ahead of the $5.69 expected on Wall Street. Revenue of $17.60 billion surpassed consensus forecasts of $16.01 billion. Strong sales of the weight-loss drug Zepbound drove the financial results.
The other catalyst has been the deal Eli Lilly reached with the TRUMP administration to provide Medicare and Medicaid coverage for the company’s weight-loss drugs. Under terms of the deal, Medicare patients will pay only $50 per month for all approved uses of injectable and oral obesity medications. The drugs currently cost consumers as much as $1,000 a month.
LLY stock has now gained 21% in the last 30 days.
Is LLY Stock a Buy?
The stock of Eli Lilly has a consensus Strong Buy rating among 20 Wall Street analysts. That rating is based on 17 Buy and three Hold recommendations issued in the last three months. The average LLY price target of $985.39 implies 0.53% downside from current levels.
